JAK2 and rheumatoid arthritis: Results demonstrated that genistein could impede angiogenesis and that angiogenesis was inhibited partially through the signaling pathway JAK2/STAT3/VEGF, providing a fresh insight into the antiangiogenic activity of genistein in rheumatoid arthritis, for which genistein may be a suitable candidate to develop a new drug for treating this disease [148].